Abbott completed its $21 billion acquisition of Exact Sciences (EXAS) on March 24, 2026, after EXAS stock surged roughly 130% in the prior 12 months. The deal folds Exact Sciences’ diagnostics business into Abbott (ABT).
Abbott Laboratories shares fell 8% on Jan. 23 after Q4 revenue of $11.5B missed the $11.8B forecast, led by an 8.9% decline in nutrition sales amid pricing pushback and higher costs.